Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

AIMS: Heart failure (HF) and type 2 diabetes (T2D), common co‐morbidities, translate into worse patient prognoses and higher direct costs than for either condition alone. Empagliflozin has been shown to markedly reduce cardiovascular (CV) deaths and HF hospitalizations (HHF) in HF patients with T2D....

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:ESC Heart Fail
Egile Nagusiak: Reifsnider, Odette S., Kansal, Anuraag R., Franke, Jennifer, Lee, Joseph, George, Jyothis T., Brueckmann, Martina, Kaspers, Stefan, Brand, Sarah B., Ustyugova, Anastasia, Linden, Stephan, Stargardter, Matthew, Hau, Nikco
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2020
Gaiak:
Original Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7754962/
https://ncbi.nlm.nih.gov/pubmed/32909680
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12985
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak